Clinical efficacy of human albumin in the treatment of progressive cerebral infarction, and its affecting factors

Objective: To explore the clinical efficacy of human albumin in the treatment of progressive cerebral infarction,and its affecting factors.Methods: Among 130 patients with progressive cerebral infarction,67 cases were treated with human serum albumin combined with symptomatic treatment(observation group),and 63 cases were treated with symptomatic treatment(control group).The blood viscosity,National Institutes of Health Stroke Scale(NIHSS) score,efficacy and adverse reaction between two groups were compared after 10 days of treatment.The affecting factors of curative efficacy were analyzed using the logistics regression.Results: Compared before treatment,the high,middle and low shear viscosity in two groups were significantly decreased after treatment(P<0.01),and the decreasing degree of which in observation group was significantly higher than that in control group(P<0.01).Compared before treatment,the NIHSS scores in two groups were significantly decreased after treatment(P<0.01),and the decreasing degree of NIHSS score in observation group was significantly higher than that in control group(P<0.01).The total efficiency rates in observation group and control group were 89.55% and 69.84%,respectively,and the treatment effect in observation group was significantly higher than that in control group(P<0.01).The incidences of adverse reaction in observation and control group were 7.46% and 1.59%,respectively,the difference of which was not statistically significant(P>0.05).Before treatment,the high shear viscosity effected significantly on the efficacy(P<0.05,OR=0.643,OR 95%CI:0.442-1.241).Conclusions: Human serum albumin in treating the progressive cerebral infarction is safe and effective,but which is affected by the blood viscosity,and worthy of clinic application.